| Literature DB >> 23913691 |
David E Ehmann1, Haris Jahic, Philip L Ross, Rong-Fang Gu, Jun Hu, Thomas F Durand-Réville, Sushmita Lahiri, Jason Thresher, Stephania Livchak, Ning Gao, Tiffany Palmer, Grant K Walkup, Stewart L Fisher.
Abstract
Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 10(1) m(-1)s(-1) for OXA-10 to 1.0 × 10(5) for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.Entities:
Keywords: Antibiotics; Drug Discovery; Enzyme Inhibitors; Enzyme Kinetics; Mass Spectrometry (MS)
Mesh:
Substances:
Year: 2013 PMID: 23913691 PMCID: PMC3784710 DOI: 10.1074/jbc.M113.485979
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157